- Home
- AMZE vs GTBP Comparison
AMZE vs GTBP Comparison
Compare AMZE & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- GTBP
- Stock Information
- Founded
- AMZE 2019
- GTBP 1965
- Country
- AMZE United States
- GTBP United States
- Employees
- AMZE N/A
- GTBP N/A
- Industry
- AMZE Beverages (Production/Distribution)
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- GTBP Health Care
- Exchange
- AMZE Nasdaq
- GTBP Nasdaq
- Market Cap
- AMZE 5.2M
- GTBP 5.5M
- IPO Year
- AMZE 2021
- GTBP N/A
- Fundamental
- Price
- AMZE $6.87
- GTBP $2.00
- Analyst Decision
- AMZE
- GTBP Strong Buy
- Analyst Count
- AMZE 0
- GTBP 1
- Target Price
- AMZE N/A
- GTBP $11.00
- AVG Volume (30 Days)
- AMZE 139.7K
- GTBP 108.9K
- Earning Date
- AMZE 08-13-2025
- GTBP 08-13-2025
- Dividend Yield
- AMZE N/A
- GTBP N/A
- EPS Growth
- AMZE N/A
- GTBP N/A
- EPS
- AMZE N/A
- GTBP N/A
- Revenue
- AMZE $254,711.00
- GTBP N/A
- Revenue This Year
- AMZE N/A
- GTBP N/A
- Revenue Next Year
- AMZE N/A
- GTBP N/A
- P/E Ratio
- AMZE N/A
- GTBP N/A
- Revenue Growth
- AMZE N/A
- GTBP N/A
- 52 Week Low
- AMZE $5.78
- GTBP $1.72
- 52 Week High
- AMZE $28.72
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- GTBP 34.07
- Support Level
- AMZE N/A
- GTBP $1.91
- Resistance Level
- AMZE N/A
- GTBP $2.31
- Average True Range (ATR)
- AMZE 0.00
- GTBP 0.31
- MACD
- AMZE 0.00
- GTBP -0.14
- Stochastic Oscillator
- AMZE 0.00
- GTBP 4.64
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.